摘要
瑞典约有220多家生物技术公司,位列世界第九位、欧洲第四位,中小企业约占93%。药物开发和生物农业是瑞典最活跃的生物科技研究领域。瑞典是国际上人类胚胎干细胞研究法律环境比较宽松的国家之一,2004年以转基因玉米为原料的特酿啤酒获准在瑞典上市。政府研发投入、种子基金、风险投资为生物医药创新及产业发展奠定了良好的投融资保障。跨国医药企业领军、中小企业自主创新、知识产权保护体系健全、合同研究机制成熟、临床研究体系发达等优势,使瑞典逐渐成为欧洲临床研究中心之一。
The number of Swedish biotechnology companies, exceeds 220 which ranks 4th in Europe, 9th in the world, and is predominant by small and medium enterprises （SMEs） with 93%. The most energetic area of Swedish biotechnology research is focusing on drug development and agro- biotechnology. The Swedish legislation on human embryo stem cell research is comparatively friendly in the world. In 2004 Sweden approved the market sale of the beer brewed by transgenic maize. The government R＆D investment, seed funds and venture capital have laid the profound foundation for the Swedish biomedicine innovation and industry development. Sweden has become one of the European medical research centers through the leadership of multinational pharmaceutical enterprises, innovations of SMEs, integrative IPR legislation, mature contract research mechanism, advanced clinical research system, and etc.
出处
《中国生物工程杂志》
CAS
CSCD
北大核心
2008年第7期6-9,共4页
China Biotechnology
